Autopsy report · NCT06337630
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
Cause of deathRegulatory or ethics
“Although no safety signal has been observed, given that the industrial development of tuvusertib has been halted regardless of the results, we see no scientific and ethical justification for continuing the study”
Life of this trial
- Registered 10 months before it started.
- Ran for about 10 months before it stopped.
- 10 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Institut Curie
- Sponsor type
- University, hospital or other
- Conditions
- Solid Tumor
- Interventions
- PLX038 + Tuvusertib
- Participants
- 10
- Sites
- 2
- Countries
- France
Trials that died the same way
- INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
“Due to the decision to discontinue the global clinical development program of tusamitamab ravtansine”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.